Skip to content
Inciteful Med

Symptoms & Warning Signs: What Your Body is Telling You

Last updated:

The earliest signs of scleroderma often include Raynaud's phenomenon, puffy fingers, and a positive ANA blood test. While skin thickening is a hallmark symptom, systemic scleroderma can also cause chronic heartburn, severe fatigue, and complications involving the lungs, heart, and kidneys.

Key Takeaways

  • • The earliest warning signs of systemic sclerosis often include Raynaud's phenomenon, puffy fingers, and a positive ANA blood test.
  • • Systemic sclerosis can affect internal organs, whereas localized scleroderma (morphea) primarily involves just the skin.
  • • Chronic heartburn, overwhelming fatigue, and joint pain are common but frequently overlooked symptoms of early scleroderma.
  • • Sudden shortness of breath, a dry cough, or sharp increases in blood pressure are medical red flags requiring immediate evaluation.

Scleroderma is often called an “invisible” disease in its early stages because the first symptoms can seem unrelated or minor. However, recognizing these signs early—especially the “red flags” for internal organ involvement—is the most important step in protecting your long-term health [1][2].

The Earliest Signs: The “Red Flag” Trio

Doctors often look for a specific trio of symptoms that suggest the body is beginning the process of systemic sclerosis. If you have all three, it is a strong signal to see a specialist immediately [1]:

  1. Raynaud’s Phenomenon: This is often the very first sign, sometimes appearing years before any other symptom [3]. In response to cold or stress, your fingers or toes may turn white (lack of blood), then blue (lack of oxygen), and finally red (blood returning) [4][5].
  2. Puffy Fingers: This is known as the edematous phase (swelling phase). Your fingers and hands may feel swollen, stiff, or “puffy,” making it hard to make a fist or wear rings [6][7].
  3. Positive ANA: A specific blood test called an Antinuclear Antibody (ANA) test will almost always be positive in people with systemic sclerosis [1].

Systemic vs. Localized: Identifying the Difference

It is important to determine which form of the disease you are experiencing, as the symptoms and risks differ significantly [8][9].

Symptom Localized (Morphea) Systemic Sclerosis (SSc)
Raynaud’s Usually absent [9] Almost always present [4]
Skin Changes Firm patches or plaques [10] Tightening of fingers and face [3]
Internal Organs Rarely affected [11] Common (Lungs, Heart, GI) [12]
Early Signs Red/purple “lilac rings” on skin [13] Puffy hands and acid reflux [6]

Overlooked Symptoms

Many patients experience symptoms that they don’t initially realize are connected to their scleroderma:

  • Gastrointestinal (GI) Issues: Chronic heartburn (GERD) is nearly universal. Other signs include feeling full very quickly after eating (early satiety), significant bloating, or sudden changes in bowel habits [14][15].
  • Profound Fatigue: This is not just “being tired.” It is an overwhelming exhaustion that can interfere with daily life [16].
  • Musculoskeletal Pain: Aching joints and muscles are common and can sometimes be the most disabling part of the early disease [17][18].

Red Flags: When the Disease Moves Inward

While skin changes are visible, some of the most serious symptoms happen where you can’t see them. You should alert your doctor immediately if you notice:

  • Lungs: A new, dry cough or shortness of breath during activities that were previously easy (like walking on level ground) [19][20].
  • Kidneys: A sudden, sharp increase in blood pressure (often called Scleroderma Renal Crisis). This is why daily home blood pressure monitoring is vital [21][22].
  • Heart: Feeling your heart race (arrhythmia) or experiencing significant swelling in your legs [23][24].

How Symptoms Change Over Time

Scleroderma often moves through phases. In the early inflammatory phase, you might experience intense itching, swelling, and “puffy” skin [25]. Over time, this may transition into the fibrotic phase, where the skin becomes thicker and tighter [26]. In some cases, the skin may eventually “soften” or become thin (atrophic phase) years later, though internal organ management remains the priority [27][28].

Frequently Asked Questions

What are the very first signs of scleroderma?
The earliest warning signs often include a specific trio of symptoms: Raynaud's phenomenon, where fingers change color in the cold, unusually puffy or swollen fingers, and a positive antinuclear antibody (ANA) blood test.
What is the difference between localized and systemic scleroderma?
Localized scleroderma, or morphea, mainly affects the skin with firm patches and rarely involves internal organs. Systemic sclerosis usually features Raynaud's phenomenon, tightening of the face and fingers, and can affect internal organs like the lungs, heart, and digestive tract.
Are gastrointestinal issues like heartburn common with scleroderma?
Yes, gastrointestinal problems are nearly universal in systemic scleroderma. Chronic heartburn or GERD, feeling full quickly after eating, significant bloating, and sudden changes in bowel habits are very common symptoms.
What symptoms indicate scleroderma might be affecting my internal organs?
New shortness of breath, a dry cough, sudden sharp spikes in blood pressure, a racing heart, or severe leg swelling are major red flags. If you experience any of these, you should alert your healthcare provider immediately.
How do skin changes progress over time with scleroderma?
Skin changes often start with an inflammatory phase that causes intense itching and puffiness. Over time, this transitions into a fibrotic phase where the skin becomes thicker and tighter, and may eventually enter an atrophic phase where it thins out years later.

Questions for Your Doctor

  • • My fingers change color in the cold; does this look like 'primary' Raynaud's or is it related to scleroderma?
  • • Can you check my nailfold capillaries under a microscope to look for early signs of vessel damage?
  • • Is the acid reflux I'm experiencing a typical sign of scleroderma, and do I need a baseline swallow study or 'esophagram'?
  • • What specific autoantibodies were found in my blood work, and what do they tell us about my risk for lung or kidney issues?
  • • Are my 'puffy fingers' considered a sign of early systemic sclerosis, and what symptoms should I watch for next?

Questions for You

  • • When you are in the cold, do your fingers change color in a specific sequence (like white to blue to red)?
  • • How much is fatigue or joint pain preventing you from doing your normal daily tasks?
  • • Have you noticed yourself getting winded or coughing during activities that used to be easy, like walking up a flight of stairs?
  • • Is your skin feeling itchy, tight, or 'thick' in specific areas, and where did those changes start?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Very Early Diagnosis of Systemic Sclerosis in Clinical Practice - Case Report and Review of the Literature.

    Marković I, Posavec AL, Morović-Vergles J, Mitrović J

    Acta dermatovenerologica Croatica : ADC 2022; (30(4)):251-255.

    PMID: 36919392
  2. 2

    Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.

    Chong WH, Saha BK, Beegle S

    The American journal of the medical sciences 2023; (365(2)):198-204 doi:10.1016/j.amjms.2022.01.023.

    PMID: 35276077
  3. 3

    Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.

    Dave J, Mahajan S, Khadilkar P, Pradhan V

    The Journal of the Association of Physicians of India 2022; (70(11)):11-12 doi:10.5005/japi-11001-0136.

    PMID: 37355940
  4. 4

    Digital Ulcers and Microvascular Abnormalities Presenting As the Initial Manifestations of Pre-scleroderma.

    Arango A, Yaman RN, Mumtaz S, et al.

    Cureus 2024; (16(12)):e75061 doi:10.7759/cureus.75061.

    PMID: 39759709
  5. 5

    Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India.

    Poonia K, Bhalla M, Dogar K, et al.

    Clinical rheumatology 2023; (42(7)):1827-1832 doi:10.1007/s10067-023-06562-3.

    PMID: 36897457
  6. 6

    Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

    Hanif I, Assassi S, Mayes MD, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(11)):1585-1595 doi:10.1002/art.43237.

    PMID: 40386907
  7. 7

    Insights into molecular and clinical characteristics of very early systemic sclerosis.

    Bellando-Randone S, Del Galdo F, Matucci-Cerinic M

    Current opinion in rheumatology 2022; (34(6)):351-356 doi:10.1097/BOR.0000000000000903.

    PMID: 36082752
  8. 8

    Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study.

    Hesselvig JH, Kofoed K, Wu JJ, et al.

    Acta dermato-venereologica 2018; (98(3)):361-365 doi:10.2340/00015555-2842.

    PMID: 29136260
  9. 9

    Morphea and Eosinophilic Fasciitis: An Update.

    Mertens JS, Seyger MMB, Thurlings RM, et al.

    American journal of clinical dermatology 2017; (18(4)):491-512 doi:10.1007/s40257-017-0269-x.

    PMID: 28303481
  10. 10

    A Case of Extensive Debilitating Generalized Morphea.

    Sapra A, Dix R, Bhandari P, et al.

    Cureus 2020; (12(5)):e8117 doi:10.7759/cureus.8117.

    PMID: 32542170
  11. 11

    Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

    Zhao M, Wu J, Wu H, et al.

    Clinical reviews in allergy & immunology 2022; (62(2)):273-291 doi:10.1007/s12016-020-08831-4.

    PMID: 33449302
  12. 12

    Cardio-pulmonary involvement in systemic sclerosis: A study at a tertiary care center.

    Arakkal G, Chintagunta SR, Chandika V, et al.

    Indian journal of dermatology, venereology and leprology 2017; (83(6)):677-682 doi:10.4103/0378-6323.198453.

    PMID: 29035287
  13. 13

    Recurrent Plaque Morphea Successfully Treated with PDO Mono Threads and Topical Tacrolimus Ointment.

    Sakhiya J, Sakhiya D, Dedakiya A, et al.

    The Journal of clinical and aesthetic dermatology 2020; (13(10)):38-41.

    PMID: 33584956
  14. 14

    Gastrointestinal involvement in systemic sclerosis: An updated review.

    Nassar M, Ghernautan V, Nso N, et al.

    Medicine 2022; (101(45)):e31780 doi:10.1097/MD.0000000000031780.

    PMID: 36397401
  15. 15

    Systemic Sclerosis, Malnutrition, and Small Bowel Obstruction: Why Clinicians Should Consider Early Total Parenteral Nutrition in Systemic Sclerosis With Severe Gastrointestinal Involvement.

    Massat B, McCarthy J

    Cureus 2022; (14(8)):e27638 doi:10.7759/cureus.27638.

    PMID: 36072159
  16. 16

    Patient perception of disease burden in diffuse cutaneous systemic sclerosis.

    Khanna D, Allanore Y, Denton CP, et al.

    Journal of scleroderma and related disorders 2020; (5(1)):66-76 doi:10.1177/2397198319866615.

    PMID: 35382406
  17. 17

    Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.

    Philip SS, Janardana R, Shenoy P, et al.

    Journal of scleroderma and related disorders 2024; (9(1)):29-37 doi:10.1177/23971983231215470.

    PMID: 38333526
  18. 18

    Immunosuppression use in early systemic sclerosis may be increasing over time.

    Park R, Nevskaya T, Baron M, Pope JE

    Journal of scleroderma and related disorders 2022; (7(1)):33-41 doi:10.1177/23971983211000971.

    PMID: 35386940
  19. 19

    Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry.

    Nagy T, Toth NM, Palmer E, et al.

    Biomedicines 2022; (10(9)) doi:10.3390/biomedicines10092129.

    PMID: 36140231
  20. 20

    Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.

    Vandecasteele E, De Pauw M, De Keyser F, et al.

    International journal of cardiology 2016; (212()):265-73.

    PMID: 27057932
  21. 21

    Kidney Transplantation in a Patient with Scleroderma.

    Bear L, Agmon Levine N, Ghinea R, et al.

    The Israel Medical Association journal : IMAJ 2024; (26(9)):593-595.

    PMID: 39397508
  22. 22

    Diffused Alveolar Hemorrhage in the Setting of Scleroderma Renal Crisis.

    Henao J, Fernandez R, Tejada Arias K, Chae C

    Cureus 2019; (11(6)):e4932 doi:10.7759/cureus.4932.

    PMID: 31431838
  23. 23

    Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.

    Noviani M, Saffari SE, Tan JL, et al.

    Seminars in arthritis and rheumatism 2020; (50(3)):473-479 doi:10.1016/j.semarthrit.2019.11.005.

    PMID: 31810742
  24. 24

    Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China.

    Hu S, Hou Y, Wang Q, et al.

    Arthritis research & therapy 2018; (20(1)):235 doi:10.1186/s13075-018-1735-4.

    PMID: 30348207
  25. 25

    Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).

    Herrick AL, Griffiths-Jones DJ, Ryder WD, et al.

    Journal of scleroderma and related disorders 2021; (6(2)):146-153 doi:10.1177/2397198320957552.

    PMID: 34222671
  26. 26

    Multimodal analyses of early, untreated systemic sclerosis skin identify a proinflammatory vascular niche of macrophage-fibroblast signaling.

    Jarnagin HC, Parvizi R, Gong Z, et al.

    JCI insight 2026; (11(3)).

    PMID: 41411065
  27. 27

    Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.

    Chung L, Spino C, McLain R, et al.

    The Lancet. Rheumatology 2020; (2(12)):e743-e753 doi:10.1016/S2665-9913(20)30237-X.

    PMID: 34966900
  28. 28

    Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.

    Utsunomiya A, Hasegawa M, Oyama N, et al.

    Modern rheumatology 2021; (31(1)):162-170 doi:10.1080/14397595.2020.1751408.

    PMID: 32243215

This page provides educational information about scleroderma symptoms and warning signs. Always consult a rheumatologist or your healthcare provider for a proper diagnosis and personalized medical advice.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.